ARS Pharmaceuticals (SPRY) Other Operating Expenses (2022 - 2026)

ARS Pharmaceuticals (SPRY) has 5 years of Other Operating Expenses data on file, last reported at $6.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 474.59% year-over-year to $6.3 million; the trailing twelve-month figure through Mar 2026 stood at $25.6 million (up 1136.84% YoY), and the FY2025 full-year result was $20.4 million, up 1990.38% from the prior year.
• Other Operating Expenses advanced to $6.3 million in Q1 2026, from $6.2 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $11.8 million in Q1 2023 to a low of -$1.1 million in Q3 2022.
• A 5-year average of $4.3 million and a median of $5.0 million in 2025 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses soared 7213.39% in 2025 and jumped 474.59% in 2026, its largest moves.
• Tracing SPRY's Other Operating Expenses over 5 years: stood at -$1.1 million in 2022, then surged by 1182.63% to $11.8 million in 2023, then slumped by 92.7% to $865000.0 in 2024, then soared by 611.45% to $6.2 million in 2025, then advanced by 2.14% to $6.3 million in 2026.
• Business Quant data shows SPRY's Other Operating Expenses at $6.3 million in Q1 2026, $6.2 million in Q4 2025, and $8.2 million in Q3 2025.